Picture [iito] Made Without Love 650x80px
Document › Details

PhoreMost Ltd.. (6/21/18). "Press Release: PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs". Cambridge.

Organisations Organisation PhoreMost Ltd.
  Organisation 2 o2h Discovery Ltd.
  Group o2h (Group)
Products Product Siteseeker® drug target discovery technology
  Product 2 medicinal chemistry
Index term Index term PhoreMost–o2h: drug discovery, 201806– collab using o2h’s medicinal chemistry to advance drug discovery projects of PhoreMost
Persons Person Torrance, Chris (PhoreMost 201504– CEO + Co-founder before Horizon Discovery Co-founder + Vernalis)
  Person 2 Shah, Sunil (o2h Discovery Ltd 201806 CEO)

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.

PhoreMost has built a pipeline of novel targets and early drug discovery programmes using its next-generation “SITESEEKER®” phenotypic screening platform. The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery.

Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. The alliance with o2h truly reflects this, and represents an important step in our mission to bring a greater diversity of therapies to patients, more quickly and at affordable prices.”

“We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs,” said Sunil Shah, CEO of o2h discovery: “Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK Biotech cluster for discovery and progressing the next generation of therapeutics.”

PhoreMost recently announced the completion of an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER” phenotypic screening platform into first-in-class drug discovery programmes.


Notes to Editors:

Dr Chris Torrance, CEO at PhoreMost Ltd
Sunil Shah, CEO at o2h Discovery Ltd
For high resolution images please contact Zyme Communications


Media enquiries

Katie Odgaard
Zyme Communications
Phone: +44 (0)7787 502 947

At PhoreMost Ltd
Dr Chris Torrance, CEO

At o2h Ltd
Sunil Shah, CEO

About PhoreMost Ltd

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

About o2h Ltd

o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co- execute to bring these ideas to life. o2h is co-located in Cambridge UK and in Ahmedabad, India and has 6 verticals covering Venture, Discovery (Services), Therapeutics, Technology, Co-work and Community.

Record changed: 2018-06-29


Picture [iito] Plain Stupid Simple 650x80px

More documents for PhoreMost Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top